These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1605593)

  • 1. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains.
    Dagan R; Bar-David Y
    Antimicrob Agents Chemother; 1992 Feb; 36(2):287-90. PubMed ID: 1605593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy.
    Mertz PM; Marshall DA; Eaglstein WH; Piovanetti Y; Montalvo J
    Arch Dermatol; 1989 Aug; 125(8):1069-73. PubMed ID: 2502950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impetigo contagiosa III. Comparative efficacy of oral erythromycin and topical mupirocin.
    Barton LL; Friedman AD; Sharkey AM; Schneller DJ; Swierkosz EM
    Pediatr Dermatol; 1989 Jun; 6(2):134-8. PubMed ID: 2501775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility of Staphylococcus aureus isolated from children with impetigo in China from 2003 to 2007 shows community-associated methicillin-resistant Staphylococcus aureus to be uncommon and heterogeneous.
    Liu Y; Kong F; Zhang X; Brown M; Ma L; Yang Y
    Br J Dermatol; 2009 Dec; 161(6):1347-50. PubMed ID: 19754868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity of antibacterials of Staphylococcus aureus isolated from impetigo patients.
    Nishijima S; Nakagawa M
    J Int Med Res; 1997; 25(4):210-3. PubMed ID: 9283995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impetigo contagiosa: a comparison of erythromycin and dicloxacillin therapy.
    Barton LL; Friedman AD; Portilla MG
    Pediatr Dermatol; 1988 May; 5(2):88-91. PubMed ID: 3045781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current options for the treatment of impetigo in children.
    Sladden MJ; Johnston GA
    Expert Opin Pharmacother; 2005 Oct; 6(13):2245-56. PubMed ID: 16218885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of erythromycin versus mupirocin for the treatment of impetigo in children.
    Rice TD; Duggan AK; DeAngelis C
    Pediatrics; 1992 Feb; 89(2):210-4. PubMed ID: 1734386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A bacteriologically controlled, randomized study comparing the efficacy of 2% mupirocin ointment (Bactroban) with oral erythromycin in the treatment of patients with impetigo.
    McLinn S
    J Am Acad Dermatol; 1990 May; 22(5 Pt 1):883-5. PubMed ID: 2112166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo.
    Goldfarb J; Crenshaw D; O'Horo J; Lemon E; Blumer JL
    Antimicrob Agents Chemother; 1988 Dec; 32(12):1780-3. PubMed ID: 3149884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The frequency of erythromycin-resistant Staphylococcus aureus in impetiginized dermatoses.
    Misko ML; Terracina JR; Diven DG
    Pediatr Dermatol; 1995 Mar; 12(1):12-5. PubMed ID: 7792212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of mupirocin and erythromycin in the treatment of impetigo.
    Britton JW; Fajardo JE; Krafte-Jacobs B
    J Pediatr; 1990 Nov; 117(5):827-9. PubMed ID: 2121951
    [No Abstract]   [Full Text] [Related]  

  • 13. Impetigo: a reassessment of etiology and therapy.
    Barton LL; Friedman AD
    Pediatr Dermatol; 1987 Nov; 4(3):185-8. PubMed ID: 3122189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of a Staphylococcus aureus Clone Resistant to Mupirocin and Fusidic Acid Carrying Exotoxin Genes and Causing Mainly Skin Infections.
    Doudoulakakis A; Spiliopoulou I; Spyridis N; Giormezis N; Kopsidas J; Militsopoulou M; Lebessi E; Tsolia M
    J Clin Microbiol; 2017 Aug; 55(8):2529-2537. PubMed ID: 28592549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the efficacy of josamycin in the treatment of impetigo in children and its in vitro activity on erythromycin resistant Staphylococcus aureus strains.
    Mosca A; Del Prete R; Mazzotta F; Bonifazi E; Miragliotta G
    J Chemother; 1995 Nov; 7 Suppl 4():158-9. PubMed ID: 8904141
    [No Abstract]   [Full Text] [Related]  

  • 16. Do Antimicrobial Resistance Patterns Matter? An Algorithm for the Treatment of Patients With Impetigo.
    Schachner LA; Andriessen A; Benjamin LT; Claro C; Eichenfield LF; Esposito SM; Keller L; Kircik L; Kwong PC; McCuaig C
    J Drugs Dermatol; 2021 Feb; 20(2):134-142. PubMed ID: 33538559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and management of impetigo.
    VanRavenstein K; Durham CO; Williams TH; Smith W
    Nurse Pract; 2017 Mar; 42(3):40-44. PubMed ID: 28178083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin-isolated, community-acquired Staphylococcus aureus: in vitro resistance to methicillin and erythromycin.
    Ohana N; Keness J; Verner E; Raz R; Rozenman D; Zuckerman F
    J Am Acad Dermatol; 1989 Sep; 21(3 Pt 1):544-6. PubMed ID: 2789236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mupirocin: a new topical antibiotic.
    Leyden JJ
    J Am Acad Dermatol; 1990 May; 22(5 Pt 1):879-83. PubMed ID: 2112165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impetigo: an overview.
    Darmstadt GL; Lane AT
    Pediatr Dermatol; 1994 Dec; 11(4):293-303. PubMed ID: 7899177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.